October 15, 2008 - Cardiogenesis Corp. sponsored an educational symposium entitled "New Horizons in Cardiac Regenerative Medicine: Advancements in Revascularization & Stem Cell Therapy," this week in conjunction with the TCT meeting in Washington, D.C.
The symposium was attended by over 120 cardiology healthcare practitioners and chaired by Warren Sherman, M.D., director of Cardiac Cell Based Endovascular Therapies, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center. Presenters included: Emerson Perin, M.D., Ph.D, director, New Interventional Cardiovascular Technology, Texas Heart Institute; Marvin Slepian, M.D., director of Interventional Cardiology, University of Arizona, Sarver Heart Center; and Keith Allen, cardiothoracic surgeon, Mid America Heart and Thoracic Surgeons, Kansas City, MO.
"The program was designed to provide an update to clinicians on the recent developments with advanced cardiovascular revascularization and regenerative therapies, with a focus on patients suffering from ischemic cardiac disease," Dr. Sherman stated. "TCT attendees are eager to learn about rapidly evolving therapies, as well as the latest information on optimizing outcomes with available tools and techniques, including TMR [transmyocardial revascularization] as a sole therapy and adjunctive to bypass surgery."
"Surgeons are innovating with Cardiogenesis to provide TMR with minimally invasive approaches, including surgical robotic delivery,” said Dr. Allen. He also discussed the early clinical experience with the PHOENIX combination delivery system being collected from centers outside the U.S.
As a leading clinical investigator of autologous stem cell trials, Dr. Perin provided a state-of-the-art overview of cardiovascular stem cell clinical trials. "The tissue-stimulated zone generated by TMR, along with the precise delivery of stem cells, may prove to be more potent in combination than either therapy alone," he explained.
For more information: www.cardiogenesis.com